Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie Inc. (NYSE:ABBV ) Piper Sandler 34th Annual Healthcare Conference Transcript December 1, 2022 9:30 AM ET Company Participants Rob Michael - Vice Chairman and President Jeff Stewart - Executive Vice President and CCO Tom Hudson - Chief Scientific Officer Scott Reents - Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay. We are going to go ahead and get started.

AbbVie Inc. (ABBV) Management Presents at Piper Sandler 34th Annual Healthcare Conference (Transcript)

Edwards Lifesciences

Intuitive Surgical

Johnson & Johnson

Eli Lilly

Merck

Walgreens

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.

Gurus Prescribed These Health Care Stocks in the 3rd Quarter

With a long track record of payouts, top dividend stock AbbVie is once again in focus, generating a strong yield with stable fundamentals The post Top Dividend Stocks: Leading Biotech AbbVie Hikes Payout appeared first on Investor's Business Daily.

Top Dividend Stocks: Leading Biotech AbbVie Hikes Payout

Kinder Morgan

Altria

The Santa Claus rally is a noted phenomenon whereby the stock market tends to rally during the week leading up to Christmas. Many theories about the reason for the phenomenon have been posited including optimism from the holiday spirit, increased shopping, and businesses settling their books before vacation.

3 Dividend Stocks to Buy in Case the Santa Rally Doesn't Come

AbbVie Inc. (NYSE:ABBV ) 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 10:55 AM ET Company Participants Jeff Stewart - Chief Commercial Officer Scott Reents - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Gavin Clark-Gartner All right. Welcome, everyone.

AbbVie Inc. (ABBV) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript)

AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Here's What's Driving AbbVie's (ABBV) Outperformance This Year

Amcor Plc

Chevron

Con Ed

McDonald's

Stanley Black & Decker

Sysco

Walmart

Dividend stocks are a great way to protect against a downturn and these are the cream of the crop.

8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income

Clorox

General Dynamics

Lowe's

It seems that the "crypto craze" is now a blast from the past. And tech stocks are no longer in vogue.

5 Great Dividend Aristocrats To Help You Sleep Well At Night

Viatris

These pharmaceutical companies are profitable and offer above-average dividends.

Better Dividend Stock: AbbVie or Viatris?

Bristol-Myers

These businesses -- and dividends -- are built to last.

3 Dividend Stocks to Hold Forever

TORONTO--( BUSINESS WIRE )--NEO is proud to welcome CIBC back to the NEO Exchange with a suite of five new Canadian Depositary Receipts (“CDRs”) to expand their existing lineup to 35 global companies.

CIBC Launches 5 New CDRs (“Canadian Depositary Receipts”) on the NEO Exchange

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

Scotts Miracle-Gro

The Best Marijuana Stocks Investors Are Watching The post 2 Marijuana Stocks To Buy Right Now Before 2023? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stocks To Buy Right Now Before 2023?

This is a stock that rewards long-term investors through continual dividend increases.

Could an Investment in AbbVie Give You $10,000 in Annual Dividend Income by Retirement?

Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today.

Philip Morris

Verizon

Exxon Mobil

High-dividend ETFs are just about the only diversified funds up this year. And most of them agree on the S&P 500 stocks you need to own.

Top Investors Reveal 7 High-Dividend Stocks You Should Own

NORTH CHICAGO, Ill. , Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022.

AbbVie to Present at the Evercore ISI HealthCONx Conference

These businesses may not be "exciting," but that's not such a bad thing right now.

2 Safe Dividend Stocks to Buy Hand Over Fist

While ABBV may outperform JNJ in the next three years, it is helpful to see how Johnson & Johnson's Peers fare on metrics that matter.

This Pharmaceutical Company Is A Better Pick Over Johnson & Johnson Stock

Shares of the pharmaceutical stock have left the S&P 500 index in the dust so far this year.

AbbVie Boosts Its Dividend: Is the Dividend King a Buy?

-        Third approved indication for SKYRIZI ®  (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) -        A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal healing and endoscopic remission at week 12 in induction studies compared to placebo 1 , 2 , 3 -        A significantly higher proportion of patients achieved clinical remission and endoscopic response at week 52 with SKYRIZI maintenance 1, 2, 3 -        Crohn's disease is a chronic, systemic inflammatory disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care4, 5 ,6 NORTH CHICAGO, Ill. , Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.1,2,3  "There are still many patients suffering from debilitating symptoms associated with Crohn's disease, such as abdominal pain and stool frequency, which is why we've embraced the challenge of serving these patients in need," said Thomas Hudson, M.D.

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease

-       Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology (ASH) annual congress NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting (December 10-13) in New Orleans, Louisiana.

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.

2 Reasons to Buy AbbVie Stock and 1 Reason to Sell

NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.

AbbVie to Present at the Piper Sandler Healthcare Conference

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

News for AbbVie Stock (ABBV)